$-0.16 EPS Expected for Avid Bioservices, Inc. (CDMO)

June 14, 2018 - By Marie Mckinney

Analysts expect Avid Bioservices, Inc. (NASDAQ:CDMO) to report $-0.16 EPS on July, 13.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.16 EPS. After having $-0.23 EPS previously, Avid Bioservices, Inc.’s analysts see -30.43 % EPS growth. The stock increased 0.55% or $0.02 during the last trading session, reaching $3.66. About 149,085 shares traded. Avid Bioservices, Inc. (NASDAQ:CDMO) has declined 14.38% since June 14, 2017 and is downtrending. It has underperformed by 26.95% the S&P500.

Avid Bioservices, Inc. operates as a contract development and manufacturing organization focusing on the development and cGMP manufacture of biopharmaceutical products derived from mammalian cell culture. The company has market cap of $203.32 million. It provides a range of process development, and cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. It currently has negative earnings. The firm produces monoclonal antibodies and recombinant proteins in batch, fed-batch, and perfusion modes; and provides services, including cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing, and regulatory strategy, submission, and support.

More notable recent Avid Bioservices, Inc. (NASDAQ:CDMO) news were published by: Seekingalpha.com which released: “Is Avid’s Backlog About To Explode?” on June 11, 2018, also Nasdaq.com with their article: “Consolidated Research: 2018 Summary Expectations for Rayonier Advanced Materials, CYS Investments, Avid …” published on June 14, 2018, Globenewswire.com published: “Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock” on June 06, 2018. More interesting news about Avid Bioservices, Inc. (NASDAQ:CDMO) were released by: Seekingalpha.com and their article: “Orgenesis, Inc. – Overlooked Stock In The Gene Therapy Contract Development With R&D Pipeline” published on June 03, 2018 as well as Streetinsider.com‘s news article titled: “HC Wainwright Starts Avid Bioservices (CDMO) at Buy” with publication date: May 24, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: